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Abstract: Osteochondral defects involve both the articular cartilage and the underlying subchondral
bone. If left untreated, they may lead to osteoarthritis. Advanced biomaterial-guided delivery of gene
vectors has recently emerged as an attractive therapeutic concept for osteochondral repair. The goal
of this review is to provide an overview of the variety of biomaterials employed as nonviral or viral
gene carriers for osteochondral repair approaches both in vitro and in vivo, including hydrogels,
solid scaffolds, and hybrid materials. The data show that a site-specific delivery of therapeutic gene
vectors in the context of acellular or cellular strategies allows for a spatial and temporal control of
osteochondral neotissue composition in vitro. In vivo, implantation of acellular hydrogels loaded
with nonviral or viral vectors has been reported to significantly improve osteochondral repair in
translational defect models. These advances support the concept of scaffold-mediated gene delivery
for osteochondral repair.
Keywords: osteochondral repair; gene therapy; tissue engineering; controlled delivery
1. Introduction
Articular cartilage, the gliding tissue covering the ends of all joints, has a reduced ability for
repair [1]. Osteochondral defects are areas of joint damage that involve both the articular cartilage and
the underlying subchondral bone (Figure 1). Such defects often result from an acute traumatic injury to
the joint or are caused by an underlying disorder of the subchondral bone, for example osteochondritis
dissecans (OCD) that secondarily affects the cartilage.
Surgical repair techniques for osteochondral defects focus on simultaneously restoring the
subchondral bone and a cartilaginous repair tissue [2]. While the quality of (osteo)chondral repair
is often regarded as a sole outcome and criterion for success, translational evidence shows that
even small lesions can be the starting point of osteoarthritis (OA) development in the vicinity of the
defect [3]. OA originating from such defects may encroach on formerly unaffected areas of the affected
compartment and progressively involve the entire joint [3]. Such OA is challenging as it may be present
long before arising to a clinically symptomatic state [4]. Long-term clinical evaluations attest to the
high rate of OA in the case of untreated large osteochondral defects such as those occurring in OCD [5].
Surgical restoration of the osteochondral unit leads to good long-term outcomes in such cases [6,7].
However, many patients suffering from advanced OA may require total joint arthroplasty, a surgical
end-stage treatment using implants that over time may pose problems such as loosening or infection.
To avoid arthroplasty, especially in younger patients, much effort has been dedicated to the treatment
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of osteochondral defects at early stages to provide for long-term repair and prevent the development
and progression of secondary OA.
Figure 1. Mechanisms of osteochondral repair. Osteochondral defects involve, by definition, both the
articular cartilage and the subchondral bone. Spontaneously, they are mainly repaired by mesenchymal
stromal cells (MSCs) arising from the subchondral bone marrow (A, yellow arrows). However, some
cell migration into the defect from synovial cells is also possible. Over time, these cells differentiate
either into chondrocytes or osteoblasts and deposit their extracellular matrix (ECM), depending on
their location within the osteochondral defect, a mechanism possibly regulated in part by paracrine
effects of the cells in the adjacent osteochondral unit (blue arrows). Ideally, a fibrocartilaginous repair
tissue forms in the upper part of the defect (B), while the subchondral bone is repaired with new bone.
Emerging treatments include cell-based and acellular, scaffold-based tissue engineering and gene
therapy. The standard cell-based therapy to repair cartilage defects is the autologous chondrocyte
implantation (ACI), with good long-term outcomes [8]. Mesenchymal stromal/stem cells (MSCs) from
the bone marrow or from connective tissues like fat are being pursued as alternatives for cartilage
repair and are applied via intra-articular administration in patients with knee OA. Early-phase clinical
studies provide some promising insight into their efficacy, but the mechanisms of action involved
remains unclear [9].
A potential advantage of gene therapy is the local delivery of gene sequences coding for therapeutic
factors with a known ability to promote both cartilage and bone reparative processes. Herein, multiple
growth factors have been identified as potent mediators to promote chondrogenesis, osteogenesis,
and/or angiogenesis [10–12]. In recent years, the successful genetic modification of cells of the
musculoskeletal system, among which articular chondrocytes and MSCs, either using viral or nonviral
vectors, has been achieved to efficiently deliver therapeutic genes, enhancing their regenerative
capacities [13,14]. Moreover, different scaffolds have been used to support the delivery of recombinant
genes and gene combinations via gene transfer using both nonviral and viral vectors to target cells
relevant of osteochondral tissue engineering and repair in vitro and in vivo. The development of such
bioactive osteochondral implants that circumvent the need for ex vivo tissue generation allows for
an in situ tissue engineering based on the active transgene product in vivo. The goal of the present
article is to provide an overview of the current advances in scaffold-mediated gene delivery for
osteochondral repair.
2. Candidate Genes for Osteochondral Repair
Polypeptide growth factors including the transforming growth factor beta (TGF-β) [15–17],
the insulin-like growth factor I (IGF-I) [18,19], and the basic fibroblast growth factor (FGF-2) [20,21] play
important roles in bone and cartilage repair by modulating ossification and enhancing the expression of
cartilage major ECM components (type-II collagen, aggrecan). Due to their potent osteogenic effects,
the members from the bone morphogenetic protein (BMP) superfamily, and particularly BMP-2, have
been applied to trigger osteogenesis and mineralization leading to the expression of bone-related markers
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(osteopontin, osteocalcin, alkaline phosphatase) [22]. The BMP-2 isoform [15], as well as BMP-7 [23],
also plays important roles in chondrogenesis by stimulating cell differentiation and the production
of the cartilage ECM. In addition, angiogenic factors such as the vascular endothelial growth factor
(VEGF) [24,25] and the platelet-derived growth factor (PDGF) [26,27] have also been described to promote
successful bone and cartilage healing via the induction of osteochondral progenitors proliferation and
proteoglycan deposition. Transcription factors as the cartilage-specific sex determining region Y-boxes
(SOX) 5, 6, and 9 (SOX5, SOX6, and SOX9, or SOX trio) [28] are also potential candidates for osteochondral
repair. These factors are critically involved in the formation and maintenance of the cartilage by activating
the expression of major matrix components. Other factors include the bone-specific Cbfa-1/runt-related
transcription factor 2 (RUNX2) [29] that modulates osteoblast differentiation with endochondral and
membranous ossification, and osterix (OSX) that is required for bone maintenance in synergism with
RUNX2 [30]. More recently, the use of messenger ribonucleic acids (mRNAs) for these various factors has
been evoked as tools for therapy, being potentially amenable to scaffold-mediated delivery in particular
for strategies that aim at initiating osteochondral repair [31–34]. Figure 2 presents an overview of the
pathways targeted by these various candidates.
Figure 2. Signaling pathways triggered by therapeutic candidates for osteochondral repair. TGF-β
promotes chondrogenesis by activating the PI3K, Smad 2/3, and RhoA pathways. FGF-2, BMP-2,
and mRNA BMP-2 induce osteo-/chondrogenesis via the RAS/RAF/MEK/MAPK and Smad pathways.
PDGF activates angiogenesis via crosstalks between the MAPK, Rho/Rac, STAT3, and PI3K pathways.
IGF-I induces the MAPK and PI3K pathways. VEGF induces angiogenesis by activating the
PLC, IP3, and FAK pathways. Abbreviations: TGF-β: transforming growth factor beta; BMP-2:
bone morphogenetic protein 2; mRNA: messenger ribonucleic acid; FGF-2: basic fibroblast growth factor;
PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor; IGF-I: insulin-like
growth factor I; ALK: activin receptor-like kinase; RAS: Rat sarcoma; RhoA: Ras homolog gene family,
member A; Rac: Ras-related C3 botulinum toxin substrate; PI3K: phosphatidylinositol-4,5-bisphosphate
3-kinase; PLC: phosphoinositide phospholipase C; FAK: focal adhesion kinase; STAT3: signal transducer
and activator of transcription 3; IP3: inositol 1,4,5-trisphosphate; Smad: suppressor of mothers against
decapentaplegic; RAF: rapidly accelerated fibrosarcoma; Akt/PKB: protein kinase B; DAG: diacylglycerol;
NOS: nitric oxide synthase; PKC: protein kinase C; RUNX2: Cbfa-1/runt-related transcription factor
2; MEK: mitogen-activated protein kinase kinase; MAPK: MAPK: mitogen-activated protein kinase;
SOX9: sex determining region Y-box 9; MMP: matrix metalloproteinase.
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3. Nonviral Gene Delivery Systems
Gene transfer via nonviral vectors (transfection) is the incorporation of the DNA plasmid (pDNA)
either alone or complexed with cationic or ionizable lipids (lipoplexes), cationic polymers (polyplexes),
or a combination of both (lipopolyplexes) [35] into the target cell population [36] (Table 1). More recent
approaches also include the use of niosomes (nioplexes) [37], dendrimers (dendriplexes) [38], and
gold or carbon nanostructures [39]. Nonviral vectors are generally considered safe carriers compared
with viral constructs as they do not carry the risk of insertional mutagenesis (nonviral vectors are kept
under episomal forms) and have a low immunogenicity (nonviral vectors have no intrinsic viral coding
sequences) [40]. However, nonviral gene transfer is characterized by a comparable low transfection
efficiency, limiting the production of high amounts of the therapeutic protein. Extensive research has
been performed during the last decades by identifying optimal promoters and designing new vectors
in order to improve their performance. Various promoters, including the human cytomegalovirus
immediate-early (CMV-IE), simian vacuolating virus 40 (SV40), and elongation factor (EF)-1 have been
tested to achieve high levels of protein expression in different cell lines and primary cell cultures [41–43].
Likewise, different pDNA conformations namely mini pDNA [44] and DNA mini-strings [45] based on
DNA-mini linear covalently closed DNA vectors have been designed, exhibiting better cytoplasmic
kinetics and improved transfection efficiently compared with parental plasmids. Alternative approaches
include the use of integrative nonviral transposon systems as those based on Sleeping Beauty [46]
or PiggyBac transposons [47]. These systems rely on the simultaneous delivery of two pDNA one
containing the gene of interest flanked by the transposase recognizable terminal inverted repeats (TIRs)
and another pDNAs containing the transposase gene. Due to its integration capacity and nonviral
nature, transposons constitute a safer alternative to the use of viral vectors in different gene therapy
protocols [48].
Table 1. Gene transfer vectors.
Systems Vectors Efficacy Integration Features
Nonviral



















adenoviral very high no short-term expression,strong immunogenicity
retroviral high yes long-term expression,strong immunogenicity
baculoviral high no short-term expression
rAAV very high no long-term expression,low immunogenicity
Abbreviations: pDNA: plasmid DNA; rAAV: recombinant adeno-associated viral vector.
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4. Viral Vectors
Recombinant viral vectors are divided into different groups according to the original type of
virus they are based upon: adenovirus, retrovirus, baculovirus, and adeno-associated virus (AAV) [49]
(Table 1).
4.1. Adenoviral Vectors
Among the viral systems employed for gene therapy, adenoviruses have been used often
because of their high transduction efficiencies and transgene expression in various types of cells,
potentially important for in vivo approaches. More than 50 adenovirus serotypes are available for
gene therapy approaches. Adenovirus serotype 5 (Ad5) has been briefly used in both in vitro and
in vivo studies. Adenoviral vectors have been used to transfer growth factor genes (TGF-β, FGF-2,
IGF-I, BMPs, and the growth and differentiation factor 5—GDF-5) into cells of the musculoskeletal
system [50–59]. Direct delivery via adenoviral-mediated transduction of IGF-I in synovial tissue in
the metacarpophalangeal joints of horses [60] and of BMP-2 injected directly in osteochondral defects
in vivo [61], or together with a decalcified cortical bone matrix as scaffold containing the vector particles
has been achieved [62]. However, the major challenges limiting the success of adenoviral approaches
are the considerable immune responses [63] particularly with a view towards a clinical applications.
4.2. Retroviral Vectors
Retroviruses have the advantage of integrating their DNA into the host genome, allowing them to
maintain gene expression for longer periods of time [64]. In comparison to the adenoviral vectors,
fewer studies employed retroviral vectors for the delivery of growth factors, such as TGF-β, SOXs,
BMPs, or VEGF inhibitors, both in vitro and in vivo [65–68]. The main problem of this kind of vector is
the risk of insertional mutagenesis and the potential activation of oncogenes. In addition, retroviral
vectors transduce only dividing cells with a restricted host range and low efficacy.
4.3. Baculoviral Vectors
Baculoviruses show no pathogenicity toward humans and can be used under biosafety level 2
conditions. Baculoviral vectors, like adenoviral vectors, have been shown to transduce both dividing
and non-dividing mammalian cells, including articular chondrocytes and adipose-derived MSCs with
TGF-β [69] and BMPs [70] in vitro and in vivo. However, baculoviral vectors are not able to replicate
and do not integrate their DNA into the chromosomes of transduced mammalian cells, resulting in a
transient transgene expression of less than 1 week. For these reasons, baculoviral vectors have attracted
less research interests and their clinical application is not permitted.
4.4. Recombinant Adeno-Associated Viral (rAAV) Vectors
AAV is a small, non-pathogenic human parvovirus that is defective for replication. It has been
genetically manipulated to form recombinant particles that lack all viral sequences and contain instead
a transgene cassette. This feature therefore makes rAAV much less immunogenic than adenoviral
gene vehicles that are not fully devoid of viral coding sequences. AAV are generally kept as stable
episomes in the target cells, which allows them to support the long-term expression of the transgenes
they carry (months to years). This characteristic further prevents the activation of oncogenes upon
insertional mutagenesis as noted when using integrative retroviral vectors. rAAV target dividing and
also non-dividing cells both at very high efficiencies, which enables direct gene transfer protocols
in vivo. For cells that remain refractory to rAAV gene transfer, research has been developed to replace
conventional rAAV vectors by pseudotyped, chimeric, hybrid, and self-complementary (scAAV)
constructs to overcome the slow viral genome conversion from single-stranded to double-stranded
DNA. Finally, the relatively limited gene delivery ability of rAAV (~4.7 kb) has been tackled by using
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the aptitude of the virus to form concatemers. Therefore, rAAV became a preferred gene transfer
system for cartilage and osteochondral repair in vivo [21,53,71–73].
5. Scaffolds for Osteochondral Repair
The ideal scaffold for osteochondral repair is biocompatible, biodegradable and provides
a three-dimensional (3D) environment, mimicking structural and biological cues of the native
osteochondral unit, aiming to support both cartilaginous and subchondral bone repair in a bioinspired
spatio-temporal fashion. Due to the differences in the mechanical properties and biological structure of
the articular cartilage and the subchondral bone, the design of scaffolds for osteochondral repair needs
to fulfill the requirements of both tissues [74]. In this scenario, the development of composite scaffolds
is centered on the design of biomaterials with adequate mechanical properties to support subchondral
bone restoration, while maintaining a comparably weaker structure allowing for cartilaginous
repair [75,76]. Such composites may comprise bilayer and multilayer scaffolds, and also continuous
gradient scaffolds [77].
Initially, the scaffold should provide a biomechanically strong support, with an adapted porous
structure to permit cellular activities, together with an appropriate in vivo degradation rate that is
in parallel to the ECM deposition. Combination of biomaterials with advanced technologies [78–83]
has allowed for developing a new generation of 3D scaffolds with adapted features for cartilage
and bone repair [84]. The technique of 3D printing has been also applied to generate osteochondral
constructs that may be tailored in the future to match the often irregular osteochondral defects. A recent
study engineered biphasic osteochondral constructs from 3D-printed fiber networks that mechanically
reinforces alginate hydrogels whilst simultaneously supporting MSC chondrogenesis [83].
A variety of biomaterials have been employed in osteochondral tissue engineering, including
hydrogels [34,82], solid scaffolds [85], and hybrid scaffolds [76]. Each are made of either natural
cell-compatible materials or of synthetic compounds with more controllable properties as mono- or
multiphasic systems (Table 2). While cells or gene vectors can be encapsulated in the 3D hydrogels, they
are usually attached to the porous structures of solid scaffolds. Hydrogels are well adapted for cartilage
repair as they have high water contents mimicking cartilage-based ECM glycosaminoglycans [86]
and biocompatibility, often with lower mechanical properties compared with solid scaffolds [87,88].
Natural polymer biomaterials such as collagen [89], alginate [90], gellan gum [91], or silk fibroin [92]
have been studied as scaffolds for cartilage repair due to their biocompatible nature promoting
proliferation and differentiation of the encapsulated cells which makes them promising systems in
various tissue engineering approaches [74,92,93]. Solid scaffolds are highly porous structures, allowing
for migration and infiltration of cells from the surrounding tissue. They may originate from natural
polymers such as poly-glycolic acid (PGA), poly (L, D-lactic-co-glycolic acid) (PLGA), polycaprolactone
(PCL), polyurethane (PU), and polyethylene terephthalate. Synthetic biomaterials synthetic as PGA and
their poly(lactide-co-glycolide) copolymers (PLGA) exhibit more reproducible physical and chemical
properties but their degradation by-products may be toxic [94]. Inorganic materials like hydroxyapatite
(HAp) have been mostly used in bone regeneration approaches, due to its exceptional mechanical
stiffness and osteoinductivity [74,76]. Metallic scaffolds based on tantalum or titanium are also
used as subchondral bone substitutes alone or in combination with other biomaterials in composite
scaffolds [95–97]. Their lack of degradation and the possibility of releasing corrosion products are
concerns to be considered [74]. Finally, a variety of hybrid scaffolds based on solid scaffolds and
hydrogels has been prepared, for example by combining fibrin hydrogels with solid PU scaffolds.
Noteworthily, biomaterial scaffolds may have a significant impact on immune responses and
foreign body reactions due to their physical, chemical, and biological properties. Herein, both the form
of biomaterial (hydrogel, solid matrix, or micro/nanoparticles), degradation profile, level of crosslinking,
hydrophobicity, topography, ad biomaterial origin (natural versus synthetic) are important parameters
to consider when designing an ideal scaffold for osteochondral repair [98].
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sustained release profiles
Abbreviations: PCL: poly(ε-caprolactone); PLGA: poly(lactic-co-glycolic acid); ECM: extracellular matrix.
Scaffold-guided gene transfer for the goal of cartilage repair (Figure 3) has been attempted using
hydrogels and polymeric micellar systems which are able to condense DNA by forming a polyplex
micelle through polyion complex formation [99,100], similarly to poloxamer PF68 and poloxamine T908
polymeric micelles, alginate-, self-assembling RAD16-I peptides- or polypseudorotaxane gels [101],
and PU scaffolds carrying rAAV vectors [102]. Such systems were employed to overexpress TGF-β [103],
an interleukin-1(IL-1) receptor antagonist (IL-1Ra), and SOX9 [102,103] as a means to safely target human
MSCs (hMSCs) [102,103] and enhance their potential for chondrogenesis and immunomodulation [103],
applied to experimental models of cartilage defects in situ for biological joint resurfacing. Moreover,
mechanical loading of these structures showed to be an advantageous strategy to promote the formation
of an ECM cartilage-like tissue [102].
Figure 3. Overview of scaffold-guided gene transfer mechanisms for osteochondral repair.
6. Scaffold-Mediated Nonviral In Vitro Gene Delivery
A large range of biomaterial scaffolds have been applied to design nonviral gene delivery
systems capable to release, in a sustainable and controlled way, therapeutic genes in desired
tissues [76,104] (Table 3) including articular cartilage [105,106] and bone [107–114]. In the field of bone
regeneration, which is of high relevance to restore the subchondral bone defect, collagen-based
scaffolds have been widely used either alone [107,109,111,112,115] or combined with ceramic
particles [109,113,114] to deliver pDNAs encoding for BMP-2 [108,110,112–114], BMP-7 [114],
TGF-β1 [105,106], PDGF [107,109,111], VEGF [108,109,113], or FGF-2 [112]. Chitosan has been widely
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used as a scaffolding material in different cartilage tissue engineering approaches due to its cationic
nature, acting as healing accelerator and exhibiting antimicrobial activities [116]. Likewise, a supporting
role for chitosan in cell proliferation has been also documented [117]. A porous chitosan scaffold
loaded with hybrid hyaluronic acid (HA)/chitosan/pDNA nanoparticles encoding TGF-β1 promoted
chondrocyte proliferation in vitro [106]. In order to design systems compatible with the structure of
osteochondral unit, different composite scaffolds were tested to optimize the regeneration of both
cartilage and subchondral bone [93,118–121]. Yi-Hsuan et al. synthetized a bilayer scaffold composed
of type-I collagen and HAp through mineralization of hydroxyapatite nanocrystals. The system
was loaded with pDNA-BMP-2 or TGF-β3/calcium phosphate multi-shell nanoparticles conjugated
with polyethyleneimine. In vitro assays showed long-term transgene expression, prompting MSCs
differentiation into osteogenic and chondrogenic lineages [121]. Recently, a fibrin-based hydrogel
activated with an mRNA coding for the transcription factor SOX9 was reported to promote MSC
chondrogenesis in vitro, with improved expression of sox9 in progenitor cells compared with the
administration of hydrogels activated with pDNA encoding for this transcription factor [122]. Similarly,
micro-macro biphasic calcium phosphate (MBCP) granules activated with an mRNA for BMP-2 were
described for their ability to support MSC osteogenic differentiation with triggered higher expression
of type-I collagen and osteocalcin relative to the use of activated fibrin hydrogels [123].
Table 3. Scaffold-mediated nonviral gene delivery.

































luc collagen-nHA rMSCs - transgene expression [115]
OSX CMC nanogel hMSCs - bone repair(osteogenesis) [131]












BMP-2 3D-printed alginatehydrogel gMSCs mouse
bone repair
(osteogenesis) [130]










BMP-2 alginate hydrogels MSCs -
bone repair
(osteogenesis) [128]
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Table 3. Cont.























BMP-2 chitosan hydrogel - rat,beagle dog
bone repair
(osteogenesis) [134]




TGF-β1 porous chitosan chondrocytes - cartilage repair(chondrogenesis) [106]
PEO-b-PLL




complexes TGF-β1 gelatin sponge rMSCs rat
cartilage repair
(chondrogenesis) [105]
TMC complexes TGF-β1 PLGA sponge BMSCs rabbit cartilage repair(chondrogenesis) [119]
superFect
complexes
BMP-2 PLGA skull-derivedosteoblasts mouse bone repair (osteogenesis) [110]
BMP-2 PEG hydrogel hFOB pig bone repair (osteogenesis) [137]
lipofectamine
complexes TGF-β1 PLGA/fibrin hydrogel rMSCs rabbit
cartilage repair
(chondrogenesis) [120]





BMP-2 CG/HCG rMSCs rabbit
osteochondral repair
(osteo-/chondrogenesis) [119]
BMP-2 alginate hydrogel hMSCs,MG-63 mouse bone repair (osteogenesis) [125]
BMP-2 alginate hydrogel gMSCs goat bone repair (osteogenesis) [127]
BMP-2 collagen and gelatinhydrogels - mouse bone repair (osteogenesis) [135]
mRNA 3DfectIN®
complexes









Abbreviations: PEI: polyethylenimine; PDGF: platelet derived growth factor; BMSCs: bone marrow-derived stromal
cells; VEGF: vascular endothelial growth factor; BMP-2: bone morphogenetic protein 2; rMSCs: rat mesenchymal
stromal cells; hPLFs: human periodontal ligament fibroblasts; hGFs: human gingival fibroblasts; FGF-2: basic
fibroblast growth factor; GFP: green fluorescent protein; luc: Firefly luciferase; nHA: nanohydroxyapatite; OSX:
osterix; CMC: carboxymethylcellulose; hMSCs: human mesenchymal stromal cells; bPEI: branched polyethylenimine;
HA: hyaluronic acid; SOX trio: sex-determining region Y-type high mobility group box 5, 6, and 9; RUNX2:
runt-related transcription factor 2; OPF: oligo polyethylene glycol fumarate; CaP: calcium phosphate; TGF-β3:
transforming growth factor beta 3; gMSCs: goat mesenchymal stromal cells; MC3T3-E1: preosteoblasts cell line;
SOX9: sex-determining region Y-type high mobility group box 9; MC: methylcellulose; BMP-7: bone morphogenetic
protein 7; ASO: antisense oligonucleotide; RAW 264.7: macrophage cell line; hPDLCs: human periodontal ligament
cells; TGF-β1: transforming growth factor beta 1; PEO-b-PLL: poly(ethylene oxide)-b-poly(l-lysine); PLGA:
poly(lactic-co-glycolic acid); rbMSCs: rabbit mesenchymal stromal cells; TMC: N,N,N-trimethyl chitosan chloride;
PEG: polyethylene glicol; hFOB: human fetal osteoblasts; hIGF-I: insulin-like growth factor I; CG: chitosan-gelatin;
HCG: hydroxyapatite/chitosan-gelatin; pDNA: plasmid DNA; mRNA: messenger RNA; MG-63: homo sapiens bone
osteosarcoma cell line; MBCP: micro-macro biphasic calcium phosphate.
7. Scaffold-Mediated Nonviral In Vivo Gene Delivery for Osteochondral Repair
Gene delivery from implantable, acellular porous scaffolds represents a versatile approach to
promote osteochondral repair by stimulating cell migration and functional tissue development in
situ. Biomaterials have been employed to deliver adsorbted nonviral vectors, enhancing their efficacy
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by delaying degradation and locally maintaining therapeutic concentrations (Table 3). For example,
a gene activated matrix (GAM) based on a multi-cistronic plasmid encoding for both BMP-2 and BMP-7
(pDNA-BMP-2/7) complexed with chitosan nanoparticles within a collagen-HA matrix promoted
osteogenesis in a critical-size calvarial defect in rats [114]. Four weeks post-implantation in vivo,
the designed system induced significantly more bone tissue formation compared with those GAM
containing pDNA-BMP-2 alone [114]. Different hydrogels scaffolds based on natural polymers such as
alginate [124–130], carboxymethylcellulose [131], chitosan [132–134], gelatin [135], or synthetic ones
such as oligo(poly(ethylene glycol) fumarate) (OPF) [136] and polyethylene-glycol (PEG) [137], have
been studied as nonviral gene delivery systems for cartilage [118,120], bone [124,125,127,130–135,137],
or osteochondral repair [93,119,121,126,128,129,136]. Mikos et al showed in a rat osteochondral defect
model that implantation of an acellular OPF-based hydrogel loaded in a spatial fashion with DNAs
encoding for RUNX2 and the SOX trio complexed with a poly(ethylenimine)-HA (bPEI-HA) delivery
vector significantly improved tissue healing relative to empty hydrogels or either factor alone [136].
Another approach uses cellularized scaffolds in the context of nonviral in vivo gene delivery.
Constructs based on a gelatin sponge scaffold loaded with MSCs and pullulan-spermine/pDNA
complexes encoding for TGF-β1 induced superior cartilage repair compared with controls at 2
months post-implantation in vivo in an osteochondral defect (2 mm in diameter, 3 mm in depth) in
rats [105]. Kelly et al developed alginate-based gene activated hydrogels by loading nanohydroxyapatite
complexed-BMP-2 and TGF-β3-DNA and MSCs [128]. These systems were able to support transfection
of encapsulated MSCs and directed their phenotype toward either a chondrogenic or an osteogenic
phenotype in vitro, depending on whether TGF-β3 and BMP-2 were delivered in combination. More
recently, 3D-printed pore-forming bioinks that maintain a sustainable transfection by modulating its
porosity were synthetized [129]. These gene-activated systems combined alginate-methylcellulose
hydrogels loaded with plasmids encoding for osteogenic (BMP-2) or chondrogenic (TGF-β3, BMP-2,
SOX9) genes. When implanted subcutaneously in mice in combination with networks of 3D-printed
thermoplastic fibers, these 3D constructs supported the development of a vascularized, bony tissue
surrounded by a cartilage layer after 4 weeks in such an ectopic location.
After orthotopic implantation of a hybrid scaffold PLGA filled with fibrin gel and loaded with MSCs
and pDNA-TGF-β1 complexed with a cationized chitosan derivative in rabbit osteochondral defects,
improved cartilage repair was evidenced at 12 weeks compared with control constructs in the absence
of pDNA-TGF-β1 or bone marrow-derived MSCs [118]. When the same scaffolds were used to deliver
PEO-b-poly(l-lysine) (PEO-b-PLL)/pDNA-TGF-β1 complexes, improved repair of both cartilage
and subchondral bone compared with controls was seen after 12 weeks in lapine osteochondral
defects [93]. A similar tendency was observed by implantation of a bilayered gene-activated
osteochondral scaffold structure with MSCs [119]. The chondrogenic layer consisted of a plasmid
TGF-β1-activated chitosan-gelatin scaffold and the osteogenic layer of a plasmid BMP-2-activated
HAp/chitosan-gelatin scaffold. When implanted in lapine osteochondral defects, this construct
appeared to qualitatively support both articular cartilage and subchondral bone repair after 12 weeks,
although no (semi-)quantitative in vivo data were presented [119].
8. Scaffold-Mediated Viral In Vitro Gene Delivery for Osteochondral Repair
Many studies immobilize active viral vectors to solid scaffolds, for example by using PLL, creating
a biomechanically functional scaffold system (Table 4). Guilak et al generated a self-contained bioactive
scaffold capable of mediating stem cell differentiation and formation of a cartilaginous ECM by
immobilizing lentiviral vectors on woven PCL scaffolds, an FDA-approved biocompatible aliphatic
polyester [138,139]. Such scaffold-mediated gene delivery of TGF-β3 induced robust cartilaginous ECM
formation by hMSCs and was as effective as traditional differentiation protocols involving medium
supplementation with TGF-β3 protein [140]. A doxycycline-inducible lentiviral vector was capable to
transduce MSCs in monolayer or in a 3D arrangement within woven PCL scaffolds to enable a tunable
IL-1Ra production as an anti-inflammatory actor. In the presence of IL-1, the IL-1Ra-overexpressing
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engineered cartilage produced cartilage-specific ECM, while resisting the IL-1-induced upregulation
of matrix metalloproteinase (MMP) and, at the same time, maintaining mechanical properties similar
to native articular cartilage. In a continuation from this study, the same group engineered functional
cartilage anatomically shaped scaffolds capable of inducible and tunable expression of IL-1Ra. Thus,
3D hemispherical scaffolds based on woven PCL fibers were fabricated and seeded with human
adipose-derived stromal cells (ASCs). Doxycycline (dox)-inducible lentiviral vectors encoding for eGFP
or IL-1Ra transgenes were then immobilized into the PCL scaffolds and constructs were cultured in
chondrogenic medium for 28 days. Constructs showed uniform tissue growth and adapted cartilage
properties while maintaining their anatomic architecture throughout culture. IL-1Ra-overexpressing
constructs produced IL-1Ra (~1 µg/mL) as a result of dox-controlled induction. Likewise, a significant
increase of MMP activity was observed in the conditioned media of eGFP-expressing constructs upon
IL-1 treatment, but not in IL-1Ra-overexpressing constructs [141]. Chondrogenesis in PCL scaffolds was
also induced in MSCs from human bone marrow by rAAV vector gene transfer of SOX9 upon. Prolonged,
effective SOX9 expression was reported in the constructs for at least 3 weeks in vitro, leading to enhanced
chondrogenic activities by deposition of proteoglycans and increased type-II collagen content in the cells
without affecting it proliferative activities. These findings reveal the therapeutic potential of providing
rAAV-modified marrow concentrates within 3D-woven PCL scaffolds [142]. Among the large variety of
solid scaffolds available for cartilage repair [143], PCL scaffolds present significant advantages as the
surface of this low immunogenic, biodegradable compound can be grafted with poly(sodium styrene
sulfonate) (pNaSS), a bioactive polymer that facilitates protein adsorption and stimulates reparative
cellular responses (adhesion, proliferation) [144]. Overexpression of sox9 in human bone marrow aspirates
via rAAV vectors delivered by PCL films functionalized via grafting with pNaSS increased chondrogenic
differentiation activities in the aspirates while containing premature osteogenesis and hypertrophy
without impacting cell proliferation, with more potent effects noted when using pNaSS-grafted films
in vitro [145]. Another study investigated the combined effect of complex mechanical stimulation and
adenoviral-mediated overexpression of BMP-2 on hMSC chondrogenesis. Human MSCs transduced
with Ad.BMP-2 were encapsulated in a fibrin hydrogel seeded into biodegradable PU scaffolds were
stimulated mechanically for 7 or 28 days in chondrogenic medium without growth factors to mimics an
in vivo environment, while controls cells were left un-transduced [146]. Transduction with Ad.BMP-2
led to a notable expression of the chondrogenic genes aggrecan and Sox9 upon mechanical stimulation.
Besides, the glycosaminoglycans (GAGs)/DNA ratios were reduced following BMP-2 overexpression
upon mechanical stimulation [146].
Table 4. Scaffold-mediated viral gene delivery.








CDM hMSCS - cartilage repair (protection againsttissue degradation) [147]
rAAV
SOX9 PU hMSCs -
cartilage repair
(cell proliferation, ECM deposition,
reduced hypertrophy)
[102]
SOX9 PCL hBMA -
cartilage repair
(cell proliferation, ECM deposition,
reduced hypertrophy)
[142]
SOX9 pNaSS-grafted PCL hBMA cartilage repair(cell proliferation, ECM deposition) [145]
TGF-β1 PEO-PPO-PEOmicelles chondrocytes -
cartilage repair
(cell proliferation, ECM deposition) [148]
SOX9 PEO-PPO-PEOhydrogel - minipig
osteochondral repair (ECM
deposition) [151]
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Table 4. Cont.




BMP-2 PU hMSCS cartilage repair(ECM deposition) [146]
BMP-2, TGF-β3 DBM BMSCs pig cartilage repair(ECM deposition) [149]
TGF-β1 PGA BMSCs mice cartilage repair(ECM deposition) [54]
SOX9 PGA BMSCs rabbit cartilage repair(ECM deposition) [150]
baculoviral TGF-β1, BMP-6 PLGA rASCs rabbit cartilage repair(neocartilage formation) [69]
Abbreviations: IL-1Ra: interleukin-1 receptor antagonist; PCL: poly(ε-caprolactone); ASCs: adipose-derived
stem cells; eGFP: enhanced green fluorescent protein; TGF-β3: transforming growth factor beta 3; BMP-2: bone
morphogenic protein 2; CDM: cartilage-derived matrix; hMSCs: human mesenchymal stromal cells; SOX9:
sex-determining region Y-type high mobility group box 9; PU: polyurethane; hBMA: human bone marrow aspirate;
pNaSS: poly(sodium styrene sulfonate); TGF-β1: transforming growth factor beta 1; PEO-PPO-PEO: poly(ethylene
oxide)-poly(propylene oxide)-poly(ethylene oxide); DBM: demineralized bone matrix; BMSCs: bone marrow-derived
stromal cells; PGA: polyglycolic acid; BMP-6: bone morphogenic protein 6; PLGA: poly(lactide-co-glycolide); rASCs:
rabbit adipose-derived stem cells; MMP: matrix metalloproteinases.
Cartilage-derived matrix (CDM) is another interesting scaffold material due to its chondroinductive
capacity and its ability to support endochondral ossification. A recent study aimed to engineer
anatomically-shaped cartilage and bone CDM constructs with the ability to inhibit inflammatory
processes. Controlled induction of IL-1Ra expression following scaffold-mediated lentiviral gene
delivery protected CDM hemispheres from inflammation-mediated degradation, and supported
robust bone and cartilage tissue formation even in the presence of IL-1. Moreover, concentric CDM
hemispheres resembling the femoral head overexpressing the chondrogenic TGF-β3, or the osteogenic
BMP-2 transgenes could be fused into a single bi-layered osteochondral construct [147].
Using hydrogels as biomaterials, controlled delivery via polymeric micelles of rAAV vectors
enhanced their temporal and spatial presentation into their targets. Delivering of rAAV vectors via
PEO and PPO (poloxamer and poloxamine) polymeric micelles as a means to overexpress TGF-β in
human OA chondrocytes resulted in increased proteoglycan deposition and higher cell numbers, thus
providing potential tools to remodel human OA cartilage [148]. Another study examined whether a
fibrin PU hybrid scaffold provides a favorable environment for the effective chondrogenic differentiation
of hMSCs overexpressing SOX9 via rAAV-mediated gene transfer when cultured in rotating bioreactors
in vitro. hMSCs could be modified via rAAV to overexpress SOX9 over an extended period within
these scaffolds, leading to an improved cell chondrogenic differentiation in such a hydrodynamic
environment relative to control (reporter lacZ) vector treatment [112].
9. Scaffold-Mediated Viral In Vivo Gene Delivery for Osteochondral Repair
Although several groups have applied transduced cells for musculoskeletal repair in
solid [54,69,149,150] or hydrogel scaffolds for cartilage [59] and bone repair [149], comparably few have
used viral vectors immobilized to scaffolds without ex vivo transduced cells for in vivo applications
(Table 4). So far, only one published study performed a biomaterial-guided in vivo delivery of a gene
vector in an orthotopic large animal model of osteochondral repair. In this study, a thermosensitive
hydrogel based on PEO-PPO-PEO poloxamers, capable of controlled release of a rAAV vector
overexpressing SOX9 was applied to a full-thickness chondral defect treated with microfracture in a
minipig model. PEO-PPO-PEO (PF127) hydrogels carrying either the candidate rAAV-FLAG-hsox9
vector (sox9/hydrogel) or a control rAAV-lacZ vector (lacZ/hydrogel) were directly applied into
defects treated with microfracture. Four weeks postoperatively, the individual histological scoring
parameters “integration”, “cellular morphology”, “matrix staining” and the total cartilage repair
score were significantly improved following the sox9/hydrogel application relative to all other groups,
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together with an increased deposition of type-II collagen in the sox9/hydrogel versus lacZ/hydrogel
defects or when applying the lacZ vector in a hydrogel-free form. Next, the apparent absence of an
immune response in all defects (lack of expression of CD3 for T-lymphocytes, of CD11b for activated
macrophages, and of human leukocyte antigen isotype DR alpha—HLA-DRα—for class II major
histocompatibility complex—MHC—antigens) supported the use of such PEO-PPO-PEO poloxamers
to protect rAAV-mediated gene transfer from neutralization by antibodies directed against the AAV
capsid. Although not directly applied to an osteochondral defect model, this study showed by
a comprehensive analyses of the entire osteochondral unit that rAAV-FLAG-hsox9/PEO-PPO-PEO
hydrogel-augmented microfracture significantly improves osteochondral repair [151].
10. Clinical Scaffolds for Osteochondral Repair
No scaffold is currently in routine clinical use that is capable of delivering a gene vector to sites of
osteochondral damage. Also, entry in clinical trials to treat osteochondral defects has been granted to
only a few scaffolds so far, among which are a nanocomposite three-layered collagen-HAp scaffold, a
PLGA-calcium-sulfate bilayer scaffold, and an aragonite-based scaffold [152]. Clinical results were
either not satisfying, or limited to a few reported case series, necessitating more high-level studies with
longer follow-up [152].
In contrast, a variety of scaffolds are in clinical development to deliver articular chondrocytes
in the context of ACI. These scaffolds can also be used either with or without cells to cover an
osteochondral defect when the bony part of the defect is filled with a bone graft or bone substitutes.
Classically, solid scaffolds are used in such clinical situations. They are composed of materials such as
type-I/III collagen (MACI™, Novocart 3D™), HA (Hyalograft® C) and PGA, polylactic acid (PLA), and
polydioxanone (BioSeed C™). More recently, hydrogels have emerged as a viable alternative, among
them type-I collagen (atelocollagen) hydrogels (Koken Atelocollagen Implant), HA (CARTISTEM™)
hydrogels, albumin and HA hydrogels (Novocart Inject™), fibrin (Chondron™), and agarose and
alginate hydrogels (Cartipatch™). Currently, not all commercial products are available for clinical use.
While these scaffolds have been used largely to deliver articular chondrocytes, they may also be used
alone as a cell-free approach.
11. Conclusions
A variety of biomaterials have been employed as nonviral or viral gene carriers for steochondral
repair in vitro, including hydrogels, solid scaffolds and hybrid scaffolds, supporting the concept
of advanced biomaterial-guided delivery of gene carriers as an attractive therapeutic option
for osteochondral repair in vivo. Such biomaterial-mediated gene therapy provides both a
template for endogenous cell migration, infiltration and tissue formation while simultaneously
promoting overexpression of therapeutic proteins in a sustained and locally determined fashion [76].
As demonstrated, a site-specific delivery of inducible transgenes confers spatial and temporal control
over both scaffold remodeling and osteochondral neotissue composition [147]. Of note, a combined
gene delivery approach may also provide immunomodulatory properties that allow for chondrogenesis
in the presence of pathologic levels of degenerative factors among which IL-1, a critical step that
may enhance the long-term success of osteochondral repair in the case of injuries or the presence of
OA [153]. Since the techniques of scaffold design are highly sophisticated, such scaffold-mediated
gene delivery may be potentially used to generate both large anatomically shaped but also cartilage
constructs individualized to the 3D defect morphology while possessing the capability for a controlled
gene delivery [141]. Moreover, the PEO-PPO-PEO copolymers controlling the release of the gene
vectors are promising biomaterials for in vivo rAAV delivery, supporting repair in conditions where
protection against potentially damaging host immune responses may be needed.
From a clinical point of view, the proven capability to deliver thermosensitive hydrogels that
display a sol-gel transition at body temperature while simultaneously controlling the release of
therapeutic gene vectors conceptually supports minimally invasive in vivo application strategies,
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an attractive feature for osteochondral defects that are located in joints that are more difficult to
access via an arthrotomy, for example, the hip joint. These current advances support the concept of a
scaffold-mediated gene delivery for osteochondral repair in the future.
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